Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
98.20    -0.80 (-0.81%)
Bid:
98.20
Ask:
99.00
Spread: 0.80 (0.815%)
Market Cap: £597.25m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Proposed changes to expense arrangements

24 Nov 2015 10:40

BACIT LIMITED - Proposed changes to expense arrangements

BACIT LIMITED - Proposed changes to expense arrangements

PR Newswire

London, November 24

BACIT LIMITED(a closed-ended investment company incorporated in Guernseywith registration number 55514)

(the "Company")

24 November 2015

Proposed changes to expense arrangements

The Company announces a proposed change to the basis on which the operating expenses of BACIT (UK) Limited, the Company’s investment manager (the “Investment Manager”), are paid with effect from 1 January 2016. The proposed change is subject to shareholder approval. 

The key features of the Company’s investment policy — that it will invest in underlying funds on a “gross return” basis, that it will invest up to one per cent. per annum of its net asset value in drug development projects and that it will donate one per cent. per annum of its net asset value to charities including the Institute for Cancer Research (“ICR”) — will remain unchanged. Both the ICR and the managers of the underlying funds in which the Company currently invests are supportive of the proposed change. 

To date, neither the Investment Manager nor the BACIT investment management team have received a fee from the Company for their investment management services. Under the proposed arrangements, the personnel costs and operating expenses of the investment management function will be covered by a new fee payable by the Company to the Investment Manager equal to 0.19% per annum of the Company’s net asset value. It is not envisaged that the Investment Manager should make a meaningful profit from the fee. Notwithstanding the proposed changes to the expense arrangements Tom Henderson will continue to provide his services as a director of the Company and as CEO of the Investment Manager free of charge. 

A circular, including a notice of an extraordinary general meeting of the Company to approve the proposed changes to the expense arrangements intended to be held at 9.30 a.m. on 11 December 2015 at the offices of Northern Trust International Fund Administration Services (Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3QL will be sent to shareholders shortly. 

A copy of the circular, when published, be available on the Company's website at http://www.bacitltd.com. The Circular will also be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

Enquiries:

Northern Trust International Fund Administration Services (Guernsey) Limited

Tel: +44 (0) 1481 745368

Date   Source Headline
12th May 202311:14 amRNSHolding(s) in Company
10th May 202312:20 pmRNSAchilles reports Q1 2023 Financial Results
4th May 202312:05 pmRNSAutolus reports Q1 2023 Financial Results
24th Apr 20233:09 pmRNSHolding(s) in Company
19th Apr 20234:57 pmRNSHolding(s) in Company
4th Apr 202312:05 pmRNSFreeline reports Full Year 2022 Financial Results
4th Apr 202312:05 pmRNSSyncona expands portfolio with £22.5m Series A
13th Mar 20237:00 amRNSUpdate re. Silicon Valley Bank
7th Mar 202312:05 pmRNSAchilles reports Q4 and full year 2022 Results
7th Mar 202312:05 pmRNSAutolus reports full year 2022 Financial Results
7th Feb 20237:00 amRNSThird Quarter Update
22nd Dec 20227:00 amRNSAutolus announces partial exercise of ADS option
12th Dec 20223:05 pmRNSAutolus presents clinical data updates at ASH
9th Dec 20227:00 amRNSAutolus announces pricing of public offering
9th Dec 20227:00 amRNSFELIX trial of obe-cel meets its primary endpoint
6th Dec 202211:05 amRNSAchilles presents clinical data update
1st Dec 20227:19 amRNSAchilles to present clinical data update
1st Dec 20227:00 amRNSSyncona completes acquisition of AGTC
29th Nov 20227:14 amRNSNeogene to be acquired by AstraZeneca
29th Nov 20227:00 amRNSSyncona extends tender offer for AGTC
17th Nov 20227:00 amRNSHalf-year Report
15th Nov 202212:05 pmRNSFreeline reports Q3 2022 Financial Results
10th Nov 20222:05 pmRNSAnaveon presents updated data from ANV419
8th Nov 202212:05 pmRNSAchilles reports Q3 2022 Financial Results
3rd Nov 20221:39 pmRNSAutolus to present clinical data updates at ASH
3rd Nov 202211:05 amRNSAutolus Reports Q3 2022 Financial Results
27th Oct 20222:58 pmRNSNotice of Results
24th Oct 20227:00 amRNSSyncona to acquire AGTC
12th Sep 20227:00 amRNSAnaveon presents updated ANV419 data
17th Aug 202210:00 amRNSApplication for admission of shares to listing
16th Aug 20227:00 amRNS1st Quarter Results
9th Aug 202212:05 pmRNSAchilles reports Q2 2022 Financial Results
9th Aug 202212:05 pmRNSFreeline reports Q2 2022 Financial Results
4th Aug 202212:07 pmRNSAutolus Reports Q2 2022 Financial Results
3rd Aug 20221:15 pmRNSHolding(s) in Company
2nd Aug 202212:28 pmRNSResult of AGM
2nd Aug 20227:00 amRNSTotal Voting Rights
15th Jul 20227:00 amRNSIssue of shares pursuant to incentive scheme
11th Jul 20227:00 amRNSFreeline presents data in haemophilia B
7th Jul 20229:41 amRNSHolding(s) in Company
30th Jun 20229:00 amRNSPublication of 2022 Annual Report & Notice of AGM
22nd Jun 20225:21 pmRNSDirector Declaration
16th Jun 20227:00 amRNSFinal Results
10th Jun 20228:05 amRNSAutolus presents clinical data updates at EHA
8th Jun 20222:33 pmRNSHolding(s) in Company
19th May 20227:00 amRNSNotice of Results
18th May 202211:05 amRNSSyncona invests in $56 million SwanBio Series B
12th May 20224:00 pmRNSAutolus to present clinical data at EHA Congress
11th May 20227:00 amRNSFreeline reports Q1 2022 Financial Results
10th May 20221:02 pmRNSAchilles reports Q1 2022 Financial Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.